IRMD as reported
IRADIMED CORPORATION reported $86M of revenue over the trailing twelve months, +15% on the year before. 10 reported series are charted on this page, each one as filed.
$86M
Revenue, trailing twelve months · to Q1 2026 · +15% against the twelve months before
- Net Income
- $24M
Net Income · +19% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $24M
Free Cash Flow · +68% year on year · trailing twelve months to Q1 2026
- Op Margin
- 32%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $86M | +15% | Q1 2026 |
| Net Income | $24M | +19% | Q1 2026 |
| EPS | $1.83 | +18% | Q1 2026 |
| Gross Margin | 77% | n/a | Q1 2026 |
| Op Margin | 32% | n/a | Q1 2026 |
| Net Margin | 27% | n/a | Q1 2026 |
| ROE | 23% | n/a | Q1 2026 |
| ROA | 20% | n/a | Q1 2026 |
| Free Cash Flow | $24M | +68% | Q1 2026 |
| P/E | 47.8 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
IRADIMED CORPORATION (IRMD) - Revenue & ProfitRevenue & ProfitIRADIMED CORPORATION (IRMD)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com